Sharda Cropchem Q4 FY26 Earnings Call Transcript Released
Sharda Cropchem reported its best-ever year in FY26 with record PAT, EBITDA, and revenue. Q4 FY26 revenue grew 13% to ₹2,065 crore, with PAT at ₹319 crore (up 57%). Full-year FY26 revenue rose 22% to ₹5,268 crore, and PAT surged 124% to ₹681 crore. The company recommended a final dividend of ₹9 per share, totaling ₹15 for FY26. FY27 revenue growth is projected at 10-15%, with EBITDA margins of 18-20%.
The announcement details a record financial year performance, strong growth across key metrics, and positive future guidance, which is highly material for investors.
The company reported its best-ever financial year with record profits and revenues, along with a significant increase in dividends, indicating a strong financial performance and positive outlook.
Sharda Cropchem Limited has released the transcript of its earnings conference call for Q4 FY2025-26, which was conducted on May 14, 2026. The call featured management, including Chairman & Managing Director Mr. R. V. Bubna and CFO Mr. Shailesh Mehendale, along with Riju Dalui from Antique Stock Broking Limited.
During the call, Mr. Bubna highlighted that FY 2025-26 was the best year in the company's history as a listed entity, achieving record annual PAT, EBITDA, and revenue despite global headwinds. He noted that total product registrations stood at 3,011 as of March 31, 2026, with 1,004 applications in the pipeline. The company expects this growth momentum to continue into FY2027.
For Q4 FY26, total revenues grew by 13% to INR 2,065 crores, with a 4% annual volume growth. The agrochemical segment grew by 5% and the non-agrochemical segment de-grew by 2%. Gross margins expanded by 750 basis points to 37.3%, and EBITDA for the quarter was INR 513 crores, a 75% increase year-on-year. PAT for the quarter was INR 319 crores, a 57% growth year-on-year. The company announced a final dividend of INR 9 per equity share, in addition to the interim dividend of INR 6, making the total dividend for FY26 INR 15 per share.
For the full year FY26, revenues reached INR 5,268 crores, a 22% increase year-on-year. The agrochemical business grew by 25% to INR 4,717 crores, while the non-agrochemical business grew by 1% to INR 551 crores. Full-year EBITDA was INR 1,040 crores, a 69% increase, and PAT stood at INR 681 crores, a 124% increase year-on-year. The company remains debt-free with cash and bank liquid investments of INR 702 crores as of March 31, 2026.
The company guided for FY27, expecting revenue growth of 10% to 15%, gross margins around 35% (plus or minus a few percentage points), and EBITDA margins between 18% to 20%. The effective tax rate for FY27 and FY28 is expected to be between 18% to 20%. The company supplies its products to approximately 70 to 75 countries globally and confirmed that the Middle East crisis is not affecting its exports or freight costs significantly.
What to do with a filing like this
Sharda Cropchem Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sharda Cropchem Limited. Read the original for the full detail.